Premium
Depot‐medroxyprogesterone acetate (DMPA) and risk of edometrial cancer
Author(s) -
Cuevas Hector Rodriguez,
Salazar Socorro Benavides,
Palet Antonio,
Ontiveros Patricia,
Silpisornkosol Suporn,
Pardthaisong Tieng,
Charoeniam Viruch,
Theetrat Shoti,
Boosiri Banpot,
Chutivongse Supawat,
Virutamasen Pramuan,
Wongsrichanalai Chansuda,
Sindhvananda Sermsri,
Koetsawang Suporn,
Rachawat Duangdao,
Kiriwat Orawan,
Koetsawang Amorm,
Scully Robert E.,
Young Robert H.,
Thomas David B.,
Stanford Janet L.,
Rosenblatt Karin A.,
Noonan Elizabeth A.,
Ray Roberta M.,
Holck Susan,
Farley Timothy M. M.,
Stanford Janet L.,
Thomas David B.
Publication year - 1991
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910490208
Subject(s) - medroxyprogesterone acetate , medicine , gynecology , medroxyprogesterone , relative risk , confounding , ovarian cancer , obstetrics , cancer , population , family planning , risk factor , research methodology , estrogen , environmental health , confidence interval
The use of depot‐medroxyprogesterone acetate (DMPA), a long‐acting progestational contraceptive, in relation to risk of epithelial ovarian cancer was examined in a hospital‐based case‐control study conducted in Mexico and Thailand. Women with histologically confirmed epithelial ovarian cancer (n = 224) diagnosed between 1979 and 1988 were compared with hospital controls (n = 1,781) matched on age, hospital and year of interview. Overall, 9.8% of cases and 12.9% of controls had ever used DMPA. The relative‐risk (RR) estimate in women who had ever used DMPA, controlling for the confounding effects of number of live births and oral contraceptive use, was 1.07 (95% CI 0.6, 1.8). No consistent patterns of increasing or decreasing risk were noted according to duration of use, time since first or most recent use or age at first use of DMPA. These results suggest that the risk of epithelial ovarian cancer is not altered by the use of DMPA.